First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

Contributed by: PR Newswire

Tags

HenliusAnti-PD-1mAb-

More Like This

Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023

PR Newswire associated0

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024